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Introduction {#sec1}
============

The intestinal microbiota contributes to many host physiological processes, including nutrient acquisition, development of the gut-specific immune system, and protection from infectious pathogens. To maintain a mutually beneficial relationship between the host and commensal microorganisms, the host immune system shapes the compositional balance of symbiotic commensal bacteria ([@bib27]). Recent studies have revealed that an imbalance in bacterial composition (dysbiosis) triggers a host pro-inflammatory immune response and induces various inflammatory and metabolic diseases ([@bib19], [@bib21], [@bib61]).

Widespread antibiotic exposure is associated with a variety of gastrointestinal effects, hypersensitivity, and drug-specific adverse effects, most notable of which is antibiotic-associated diarrhea (AAD) in 5%--35% of treated patients ([@bib63], [@bib44]). Non-selective antibiotic-induced dysbiosis accounts for up to 20% of all AAD cases ([@bib4]). Probiotics have been proposed to constitute an effective preventive treatment for antibiotic-induced dysbiosis and associated adverse effects in mice ([@bib18], [@bib26]). Multiple *in vitro* studies have confirmed that probiotics can prevent an increase in colon epithelial cell permeability and can play a role in repairing damage to the intestinal epithelial barrier ([@bib32], [@bib52]).

The gram-positive obligate anaerobic bacillus, *Clostridium butyricum* (CB), exists in the soil, and in animal and human intestines. Specifically, *Clostridium butyricum* MIYAIRI 588 (CBM 588) is a probiotic bacterium that has been used in the treatment of various human gastrointestinal diseases in Japanese clinical settings ([@bib55]). Our previous *in vivo* study showed that treatment with CBM 588 reduced gut epithelial damage caused by antibiotic administration, in addition to reducing superficial epithelial necrosis and the presence of inflammatory cells ([@bib24]). Other studies have suggested that CBM 588 can directly supplement butyrate during the repair of damaged intestinal mucosa, as a kind of butyrate-producing probiotic ([@bib15]). An *in vivo* study demonstrated that CBM 588 also induces intestinal IL-10-producing macrophages to suppress acute experimental colitis induced by dextran sulfate sodium (DSS) ([@bib25]). However, the underlying mechanism by which CBM 588 protects the gut epithelial barrier remains unclear both during and after antibiotic treatment.

To elucidate this mechanism, we investigated the immunological and metabolic interaction between the host and gut microbiome under antibiotic-induced dysbiosis. This work reveals two novel protective mechanisms of epithelial cells in the colon under CBM 588 treatment. First, CBM 588 induces IL-17A-producing γδT cells and IL-17A-producing CD4 cells in the colonic lamina propria (cLP), thus enhancing gut epithelial barrier function under antibiotic-induced dysbiosis. Second, CBM 588 plays an important role in controlling antibiotic-induced gut inflammation through upregulation of anti-inflammatory lipid metabolites such as palmitoleic acid, 15d-prostaglandin J~2~, and protectin D~1.~ This study provides new insights into gut epithelial barrier protection with probiotics under conditions of antibiotic-induced dysbiosis.

Results {#sec2}
=======

Antibiotics Compromise Gut Epithelial Integrity {#sec2.1}
-----------------------------------------------

Mounting evidence suggests that commensal *Clostridium* strains have major effects on the development of the gut immune system, thereby regulating gut homeostasis ([@bib2], [@bib30]). Although CBM 588 has a major impact on the treatment of gastrointestinal diseases, the precise mechanism by which it prevents epithelial damage remains to be elucidated. To determine whether colonization by CBM 588 has an immunomodulatory and metabolic role in regulating gut homeostasis, we administered clindamycin and/or CBM 588 to ICR mice for 4 days ([Figure 1](#fig1){ref-type="fig"}A). We confirmed that colonization of CB was retained in the colon even after clindamycin administration ([Figure 1](#fig1){ref-type="fig"}B). The spore colony counts for the CBM 588 administration group and combination (clindamycin + CBM 588) group were similar to the total CB colony count in each group throughout the study period. The CBM 588 administration group showed the highest CB colony counts at day 2, and the counts rapidly decreased after CBM 588 administration was discontinued. During the treatment period, CB counts also increased in the combination group and decreased after CBM 588 administration was discontinued. However, bacterial regrowth was observed in the combination group, and the highest CB colony counts were on day 8. During the study period, CBM 588 showed a slight effect on body weight and no effects on stool consistency. The body weight of ICR mice was increased by CBM 588 administration and was not attenuated in mice given clindamycin ([Figure 1](#fig1){ref-type="fig"}C). Macroscopic findings revealed a slightly shortened colon length in mice administered CBM 588 ([Figure 1](#fig1){ref-type="fig"}D). We expected the clindamycin administration group to show shorter colon compared with the other group. However, our study showed the opposite result with previous *in vivo* study with colitis model induced by DSS, whereas the reason was unclear ([@bib25]). In histological examination, only the clindamycin administration group samples showed abnormalities at day 8, such as (1) superficial epithelial necrosis and (2) presence of inflammatory cells, including mainly neutrophil infiltration ([Figure 1](#fig1){ref-type="fig"}E). In contrast, CBM 588 administration group samples showed histologically normal colon mucosa, even though clindamycin was administered concurrently. Compared with the control and CBM 588 groups, the clindamycin administration group showed a significantly higher histological inflammation score ([Figure 1](#fig1){ref-type="fig"}F). Although there was no significant difference, the combination group showed a numerically lower score than that of the clindamycin administration group. Additionally, we also noticed that the clindamycin administration group had significantly more epithelial damage in the colon ([Figure 1](#fig1){ref-type="fig"}G). Protective effects of CBM 588 on colon mucosa have also been observed in the acute DSS colitis model ([@bib25]). Similar to our previous study ([@bib24]), we found that CBM 588 administration prevented the development of clindamycin-induced colitis. However, the mechanism by which CBM 588 protects the colon from antibiotic damage remains unclear. To address this, we assessed gut microbiome, cytokine profiles in isolated colon tissue, and metabolic profile alternations in gut microbiome and host gut colon tissue.Figure 1Mice Suffer Worse Epithelial Injury after Clindamycin Administration(A) Experimental design of clindamycin and/or CBM 588 administration in 9- to 10-week-old ICR mice. Mice received clindamycin and/or CBM 588 via sonde for 4 days; 1: control group (Control), 2: clindamycin administration group (CLDM), 3: CBM 588 administration group (CBM 588), and 4: combination (CBM 588 + clindamycin) group (Combination). Collection time points of stool for *C. butyricum* colony count and microbiome analysis and colon tissue for cytokine and macroscopic analysis are indicated.(B) Enumerating *C. butyricum* in feces in ▲: total colony count in CBM 588 administration group (CBM 588-T), ▵: spore colony count in CBM 588 monotherapy group (CBM 588-AS), ●: total colony count in combination group (Combination-T), ○: spore colony count in combination group (Combination-AS). The testing detectable level is above 2.3 (log amount) in per gram feces, with representative data n = 5--10 per group, mean ± SEM. Statistical analysis of quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.(C) Weight changes of control group (●), CBM 588 administration group (▲), clindamycin administration group (■), and combination group (◆) for mice over time duration of the study (18 days), with representative data n = 5 per group, mean ± SEM.(D) Colon length (cm) at day 8, with representative data n = 5 per group, mean ± SEM. Pictures show representative isolated colons from each group. Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.(E) Hematoxylin and eosin (H&E) staining of colons at day 8 revealed superficial epithelial necrosis and the presence of inflammatory cells only in the clindamycin administration group (magnification, 10× and the scale bar represents 150 μm).(F) Histopathology scoring of H&E-stained colon sections in each group mice. All values are mean ± SEM (n = 5). Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.(G) Intestinal permeability was determined. All values are mean ± SEM (n = 5). Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.

CBM 588 Modulates the Gut Microbiome Composition under Clindamycin-Induced Dysbiosis {#sec2.2}
------------------------------------------------------------------------------------

To reveal the impact of CBM 588 on the gut microbiome under antibiotic treatment conditions, we conducted gut microbiome analysis. Changes to the murine gut microbiome at the phylum level, after either 4 or 8 days, is shown in [Figure 2](#fig2){ref-type="fig"}A. Bar graphs depict the mean percent abundances of bacterial families (≥1% relative abundance). Intestinal flora mainly consisted of members of the Firmicutes (Clostridiales, Lactobacillus) and Bacteroidetes phyla (Bacteroidales, Bacteroides) in the control group and CBM 588-administered group, respectively. Clindamycin administration resulted in dramatic increases in Proteobacteria phylum. However, the presence of members of the Bacteroidetes phylum dramatically decreased, and Firmicutes phylum members also decreased, although a dramatic increase was observed at day 8. Gut microbiome modification for the combination group was similar to that of the clindamycin administration group, at the phylum level.Figure 2CBM 588 Modulates Gut Bacterial Composition in Mice(A) Bacterial compositions in different experimental groups at the phylum level. 4d: sampling at day 4, 8d: sampling at day 8.(B) Comparison of the Shannon index of different groups. The box and whiskers represent the smallest and largest values, with the median in the center of each box.(C) Principal Coordinate Analysis (PCoA) based on weighted Unifrac distances among four groups.(D) PCoA based on weighted Unifrac distances between the clindamycin administration group and the combination group.(E) The bacterial composition at day 4 in the clindamycin administration group and combination group at the family level.(F) Effect of clindamycin and CBM 588 administrations on relative species abundance (≥0.001%) in the fecal samples. After quality filtering steps, three species (*Bifidobacterium*, *Lactobacillus*, and *Lactococcus*) were considered to have significantly higher relative abundance (%) in the combination group, compared with the clindamycin administration group at day 4. Data represent the mean values of relative abundances ±SEM (n = 5--10). Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.

To determine bacterial richness and diversity in the gut microbiome, we calculated α-diversity and β-diversity based on fecal samples for all groups. Clindamycin exposure significantly decreased α-diversity (p \< 0.05) ([Figure 2](#fig2){ref-type="fig"}B). A similar trend was observed in bacterial α-diversity over time in both groups, as there were no significant differences between the clindamycin administration group and combination group. Also, both groups did not recover α-diversity during the study period. The control group and CBM 588 administration group exhibited stable scores in α-diversity at day 4 and day 8. At two time points, no significant difference in α-diversity was also observed between the control group and CBM 588 administration group. PCoA based on the weighted Unifrac distance metric is shown in [Figure 2](#fig2){ref-type="fig"}C. There was no significant change in bacterial community composition for the CBM 588 administration group and control group at day 4 and day 8. However, bacterial communities in the clindamycin administration groups (including the combination group) clustered separately (p \< 0.05) from the control group at days 4 and 8 ([Figure 2](#fig2){ref-type="fig"}C), whereas bacterial communities in fecal samples of the clindamycin administration group and combination group did not cluster separately from each other at day 4 and day 8. However, bacterial communities of the combination group clustered separately from the clindamycin group at day 4 (p \< 0.05), when compared with only two groups ([Figure 2](#fig2){ref-type="fig"}D). These data suggest that the impact of clindamycin on the gut microbiome was much greater than that of CBM 588. However, CBM 588 does have some effect on the gut microbiome, since the microbial composition of the clindamycin administration group and combination group were different during the CBM 588 administration period, whereas differences were less when compared with the control group.

We then investigated murine gut microbiome changes at the genus and species level at day 4 ([Figure S1](#mmc1){ref-type="supplementary-material"}). The relative abundance of various families with percentages of sequences ≥0.001% of the bacterial community was analyzed ([Figure 2](#fig2){ref-type="fig"}E). The intestinal flora mainly consisted of *Enterobacteriales* for the clindamycin administration group and combination group, and CBM 588 administration resulted in dramatic increases in the *Lactobacillales* and *Bifidobacteriales* genera. However, the *Clostridiales* genera were reduced in the combination group. The relative abundance (%) of three species (*Bifidobacterium*, *Lactobacillus*, and *Lactococcus*) in the combination group were significantly increased compared with that in the clindamycin administration group at day 4 ([Figure 2](#fig2){ref-type="fig"}F). *Bifidobacterium* abundance was increased in the combination group, but relative abundances of *Bifidobacterium* in the control and clindamycin administration groups were nearly zero during the study period. *Lactococcus* in the combination group showed a higher relative abundance at day 4 than that seen in the other groups. *Lactobacillus* for only the clindamycin administration group was reduced at day 4, and microbiome analysis revealed that clindamycin induced gut dysbiosis in mice. Microbiomes were similar at the phylum level between the clindamycin administration group and combination group. However, CBM 588 impacted the gut microbiome, and some species, such as *Bifidobacterium*, *Lactobacillus*, and *Lactococcus*, exhibited an inverse correlation between the combination group and clindamycin administration group. These results suggest that clindamycin administration reduces diversity in the gut microbiome, even with concurrent administration of CBM 588. However, the composition of the microbiome was significantly different between the clindamycin administration group and the combination group. Therefore, these results support the hypothesis that host physiological processes to maintain gut homeostasis are affected differently in the clindamycin group and combination group under CBM 588 treatment.

CBM 588 Modulates Cytokine Expression to Regulate Gut Inflammation under Antibiotic-Induced Dysbiosis {#sec2.3}
-----------------------------------------------------------------------------------------------------

Next, we sought to elucidate the mechanisms of gut epithelial protection exerted by an altered gut microbiome after CBM 588 administration. To address this, we isolated colon tissues from mice and assessed cytokine profiles with qPCR (the sequences of primers are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}) and ELISA. CBM 588 is known to exhibit a colitis-preventing effect in different experimental colitis models ([@bib25]), and a previous study revealed that CBM 588 promotes Treg cell generation through induction of transforming growth factor β~1~ (TGF-β~1~) by dendritic cells (DCs) in a DSS-induced acute colitis model ([@bib35]). Consistent with this previous report ([@bib35]), CBM 588 administration enhanced the expression of TGF-β~1~ RNA ([Figure 3](#fig3){ref-type="fig"}A) and TGF-β~1~ protein ([Figure 3](#fig3){ref-type="fig"}B), compared with the clindamycin administration group and control group in this study. Although CBM 588-mediated TGF-β~1~ induction was mainly Toll-like receptor-2 (TLR-2) dependent, and the ERK-AP-1 kinase pathway played an important role ([@bib35]), our study revealed that TLR-2 RNA expression levels increased with CBM 588 administration ([Figure 3](#fig3){ref-type="fig"}C).Figure 3CBM 588 Modulates Inflammation and Anti-inflammation Cytokines to Suppress Antibiotic-Induced Colitis(A) The relative RNA expression levels of genes encoding TGF-β~1~ in colon tissue of mice detected at day 8 by qPCR.(B) TGF-β~1~ protein concentrations in colon tissues of mice detected at day 8 by ELISA.(C) The relative RNA expression levels of genes encoding TLR-2 in colon tissue of mice detected at day 8, as detected by qPCR.(D) The relative RNA expression levels of genes encoding IL-1β, IL-6, TNF-α, COX-2, INF-γ, and IL-10 in colon tissue of mice at day 8, as detected by qPCR.(E) TNF-α protein concentrations in colon tissues of mice detected at day 8, as measured by ELISA.(F) The relative RNA expression levels of genes encoding NF-κB and HSP-70 in colon tissue of mice detected at day 8, measured by qPCR.(G) Hematoxylin and eosin (H&E) staining of colons in the clindamycin group shows the presence of inflammatory cells at day 8, including many neutrophil infiltration after clindamycin administration (left: magnification, 10× and the scale bar represents 150 μm) (right: magnification, 20×).All values are mean ± SEM (n = 5--10). Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.

Additionally, we found that various inflammatory cytokines were upregulated in the clindamycin administration group ([Figures 3](#fig3){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}). However, consistent with previous report findings for the concurrent administration of CBM 588 ([@bib25]), we found that CBM 588 reduced RNA expression levels of inflammatory cytokines, including interleukin-1β, IL-6, interferon-γ (INF-γ), cyclooxygenase-2 (COX-2), and tumor necrosis factor alpha (TNF-α), while increasing IL-10 RNA expression levels in colonic tissue on day 8 after antibiotic treatment ([Figure 3](#fig3){ref-type="fig"}D). Likewise, TNF-α protein levels were also reduced with CBM 588 administration ([Figure 3](#fig3){ref-type="fig"}E). Another previous study revealed that the TGF-β~1~ pathway regulates inflammatory cytokines and promotes IL-10 cytokine production ([@bib25], [@bib29]). These data suggest that the anti-inflammatory effect of CBM 588 on clindamycin-induced colitis is associated with a TGF-β~1~-dependent reduction of inflammatory cytokine expression and increase in anti-inflammatory cytokines. Also, for the CBM 588 administration groups, including the combination group, regulation of NF-κB and HSP-70 RNA expression levels was observed ([Figure 3](#fig3){ref-type="fig"}F). Although RNA expression is not the standard method used to assess NF-κB activation, these results might support a suppressive effect of CBM 588 on the migration and infiltration of leukocytes in the colon tissue ([Figure 3](#fig3){ref-type="fig"}G). In addition, antibiotic-induced dysbiosis occurs rapidly within several days, leading to altered bacterial metabolism and an impaired host proteome in mice and humans ([@bib20], [@bib38]). Taken together, we found that clindamycin administration caused gut inflammation and CBM 588 modulated gut cytokine expression under antibiotic-induced dysbiosis through the TGF-β~1~ pathway, which is similar to previous studies using other murine DSS-induced colitis models ([@bib35], [@bib25]). However, this signaling pathway did not enhance IgA antibody production from Treg cells in this study ([Figure S3](#mmc1){ref-type="supplementary-material"}), which was like a previous study using a DSS-induced colitis model ([@bib35]). The reduction of some inflammatory cytokines in the CBM 588 administration groups indicates that CBM 588 may have an effect on tight junction proteins of epithelial columnar cells and may change metabolic profiles in colonic tissue to reduce inflammation.

CBM 588 Promotes the Expansion of IL-17A-Producing γδT Cells and CD4 Cells in Colonic Lamina Propria to Maintain Gut Epithelial Barrier Integrity {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------------------------------

The intestinal barrier is established by epithelial columnar cells and is built of monolayered columnar epithelial cells that are tightly connected by tight junction proteins (TJs) such as occludin (OCLD), zonula occludens-1 (ZO-1), and claudins-4 (CLDN4) ([@bib62]). TJs are the structural feature that help prevent the entry of laminal antigens and microorganisms ([@bib14]). The secretory protein mucin-2 (MUC-2) is also the primary component of the protective mucous layer in the colon ([@bib64]). To further characterize the protective effects of CBM 588 on the epithelial layer during antibiotic administration in mice, we determined MUC-2, ZO-1, CLDN4, and OCLN RNA expression levels in mouse colon tissue by qPCR. Our results indicate that CBM 588 upregulated RNA expression levels for all these genes ([Figure 4](#fig4){ref-type="fig"}A). CBM 588 administration also enhanced MUC-2 and ZO-1 protein expressions ([Figure 4](#fig4){ref-type="fig"}D). Although TJs are normally considered part of the physical barrier, they are largely affected by mucosal immune homeostasis within cLP as well as the composition of gut microbes and thus can be regarded as a translator between the microbiome and immune system ([@bib42], [@bib46], [@bib1]). Several studies have revealed impaired TJ complexity and the downregulation of TJs in ulcerative colitis (UC), which could be a mechanism contributing to dysfunction of the intestinal barrier. In this study, CBM 588 increased mucin production and TJ expression levels, which have been found to lead to greater epithelial barrier integrity ([@bib47], [@bib49]).Figure 4CBM 588 Enhances Intestinal Barrier Function of Colitis Mice(A) The relative RNA expression of genes encoding mucin-2 (MUC-2), claudin (CLDN4), zonula occludens (ZO-1), and occludin (OCLN) in colon tissues of mice, detected by qPCR.(B) The relative RNA expression levels of genes encoding IL-17A in colon tissues of mice, detected by qPCR.(C) The IL-17A concentration in each animal group was detected by ELISA.(D) The MUC-2 and ZO-1 concentrations in each animal group were detected by ELISA.All values are mean ± SEM (n = 5--10). Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.

Moreover, previous studies have shown that, after acute intestinal injury, the intestinal-protective cytokine IL-17A could regulate TJs to limit excessive permeability and maintain barrier integrity ([@bib37]). We therefore tested IL-17A RNA expression levels and IL-17A protein levels in the colon tissue and found that CBM 588 induced an increase in IL-17A levels in colon tissue at day 8 ([Figures 4](#fig4){ref-type="fig"}B and 4C). Mucosal T cells in cLP are master cells that play an important role in maintaining intestinal barrier homeostasis. Among the immune cells dwelling in intestinal mucosa, γδT cells are rare T cell subsets that have been found to be involved in both pathogenic and protective networks in inflammatory bowel disease (IBD) ([@bib48]). γδT cells in intestinal LP were found to be the major source of gut-protective IL-17A, and this γδT cell-derived IL-17A was found to promote the repair of damaged intestinal epithelium through adaptor molecule Act1-mediated regulation of TJ subcellular localization ([@bib37]). Therefore, we hypothesized that IL-17A-producing γδT cells may be involved in the protective mechanism of CBM 588 on colon mucosa. IL-17A-producing γδT cells provide an immediate source of IL-17A at barrier sites, which supports a pro-inflammatory immune function. To investigate whether protective effects of CBM 588 were associated with the upregulation of IL-17A-producing γδT cells, we further isolated the lymphocytes in cLP and found an upregulation of γδT cells and IL-17A-producing γδT cells in the mouse combination group ([Figures 5](#fig5){ref-type="fig"}A and 5B), whereas no IL-17A-producing γδT cells were detected in the clindamycin administration group (p \< 0.05). Additionally, as some other immune cells can produce IL-17A, such as Th17 cells and ILC3, we conducted additional evaluations of IL-17-producing CD8, CD4, and ILC3 cells in lamina propria ([Figures 5](#fig5){ref-type="fig"}C, 5D, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B) to clarify that CBM 588 affects other IL-17-producing cell populations. Consequently, CBM 588 were associated with the upregulation of CD4 cells and IL-17A-producing CD4 cells ([Figure 5](#fig5){ref-type="fig"}D). On the other hand, CD8 cell and ILC3 cell frequencies were not changed with CBM 588 (data not shown). Previous study results revealed that IL-17A produced by γδT cells and CD4 cells also activated the Act-1 pathway in epithelial cells to maintain barrier integrity ([@bib37]) owing to the upregulation of MUC-2 production and strengthening of TJs attachments ([@bib62], [@bib37]). Additionally, CBM 588 does not ameliorate the colitis induced by clindamycin by using anti-IL-17A antibody ([Figures 6](#fig6){ref-type="fig"}A and 6B). IL-1β, TNF-α, and COX-2 RNA expressions were upregulated with anti-IL-17 antibody in CBM 588-treated mice, whereas IL-6 RNA expression was unaffected. Hence, the results suggested that IL-17 produced by γδ T cells and CD4 cell play an important role in protecting the colon from inflammation damage. Taken together, this study indicates that potential protective effects of CBM 588 on the intestinal barrier can be elucidated using an antibiotic-induced colitis model in ICR mice. CBM 588 upregulated the expression of IL-17-producing γδT cells and CD4 cells. Previous study identified three major RORgt + populations (γδT cells, CD4 cells, and ILC3s) in the colon after DSS treatment, and intracellular staining for IL-17A and IL-22 revealed that γδT cells were the major source of IL-17A in the cLP after DSS-induced injury, with more than 30% of cells expressing the cytokine and very few IL-22-producing γδT cells. In contrast to γδT cells, CD4 T cells only had a minor contribution to IL-17 and IL-22. Very few ILC3 cells were positive for IL-17A ([@bib37]). Our results show that CBM 588 administration results in elevation of γδT cells and CD4 cells in cLP of mice and also upregulates IL-17A-producing γδT cells and CD4 cells in cLP. This helps preserve the integrity of antibiotic-damaged epithelial surfaces through the upregulation of TJs as well as mucin production.Figure 5CBM 588 Upregulates IL-17A-producing γδT Cells and CD4 Cells(A) Representative flow cytometry plots of γδT cells identified, and IL-17A-producing γδT cell expression among lymphocytes in colonic lamina propria (cLP) in the control group (Control), CBM 588 administration group (CBM 588), clindamycin administration group (CLDM), and combination group (Combination).(B) Percentage of γδT cells in lymphocytes of cLP for the clindamycin administration group (CLDM) and combination group (left). Percentage of IL-17A secreting γδT cells among γδT cells in cLP cells (right).(C) Representative flow cytometry plots of CD4 cells identified, and IL-17A-producing CD4 cell expression among lymphocytes in cLP in the control group (Control), CBM 588 administration group (CBM 588), clindamycin administration group (CLDM), and combination group (Combination).(D) Percentage of CD4 cells in lymphocytes of cLP for the clindamycin administration group (CLDM) and combination group (left). Percentage of IL-17A secreting CD4 cells among CD3 cells in cLP cells (right).All values, except [Figures 5](#fig5){ref-type="fig"}A and 5C, are mean ± SEM (n = 5--10). Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05, n.d., not detected.Figure 6Anti-IL-17 Antibodies Reduced CBM 588 Effects on Intestinal Barrier Function(A) The relative RNA expression levels of genes encoding IL-1β, IL-6, TNF-α, and COX-2 in colon tissue of mice detected at day 8 by qPCR. Expression of target genes was analyzed by the ΔΔCt method. Relative RNA expression levels of each target gene in mice treated with combination (clindamycin + CBM 588) + Anti-IL-17 antibodies were normalized to the combination group (represented as RQ).(B) Hematoxylin and eosin (H&E) staining of colons at day 8 revealed superficial epithelial necrosis and the presence of inflammatory cells only in mice treated with combination (clindamycin + CBM 588) + Anti-IL-17 antibodies (magnification, 4× and the scale bar represents 150 μm).All values are mean ± SEM (n = 5--10). Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05, n.d., not detected.

CBM 588 Changes Gut Microbiome Metabolic Profiles to Protect the Gut Epithelial Barrier {#sec2.5}
---------------------------------------------------------------------------------------

Next, to elucidate the impact of CBM 588 on the underlying epithelial barrier protective mechanism against antibiotic damage, we investigated gut metabolic alterations by the resident microbiome. Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used to obtain relative Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway abundance information derived from metagenomics data ([@bib36]) ([Figures 7](#fig7){ref-type="fig"}A and 7B). We found that the activities of detailed metabolic pathways showed considerable variation. The combination group had a metabolic pathway activity similar to that of the clindamycin administration group. On the other hand, the combination group had higher relative activity compared with the clindamycin administration group, especially for "starch and sucrose metabolism" and "fructose and mannose metabolism" under carbohydrate metabolism ([Figure 7](#fig7){ref-type="fig"}C). Certain bacteria of the intestinal flora are beneficial for gut health. Apart from immunomodulating capacities, these bacteria can also improve mucosal barrier integrity ([@bib41]). Hence, microbiome changes during CBM 588 treatment may contribute to attenuation of colon epithelial damages. Antibiotic-induced alteration of the mucous layer can lead to breaches in the epithelial barrier by specific bacteria, resulting in immune responses leading to chronic inflammation ([@bib24]). Considering the increased abundance, only in the combination group, of bacterial species such as *Bifidobacterium*, *Lactobacillus,* and *Lactococcus,* that can use starch, sucrose, fructose, and mannose as energy sources, it appears that CBM 588 indirectly enhanced starch, sucrose, fructose, and mannose metabolism to produce glucose. Since mucin is an important source of carbohydrates for commensal bacteria, gut mucosal microbiome in inflamed regions can shift toward bacteria that metabolize "starch, sucrose, fructose and mannose" to maintain fixed amounts of energy production through the activation of carbohydrate metabolism ([@bib34]). Therefore, we believe that CBM 588 caused gut microbiome functional shifts toward increased carbohydrate metabolism through gut microbiome alternations.Figure 7CBM 588 Changes Gut Microbiome Metabolic Profiles to Protect the Gut Epithelial Barrier(A) Heatmaps, generated by hierarchical clustering, of selected colon metabolites at day 4, were significant between the control, clindamycin, and/or CBM 588 administration groups by Kruskal-Wallis test. An FDR p value \< 0.05 was considered statistically significant, and the Benjamini-Hochberg method was used to calculate FDR p value.(B) Expansion sites derived from [Figure 7](#fig7){ref-type="fig"}A.(C) Comparison of the relative abundance of "starch and sucrose metabolism" and "fructose and mannose metabolism" in individual groups.(D) The concentration of SCFAs in fecal samples. These fecal samples were taken at day 4 and day 8.(E) The ratio of n-butyrate/lactate among all groups at day 4 and day 8.(F) Comparison of the relative abundance of "lipid metabolism," "arachidonic acid metabolism," and "α-linoleic acid metabolism" in individual groups.All values are mean ± SEM (n = 5--10). Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.

In addition, we detected various metabolites in feces produced by the resident microbiome. Short-chain fatty acids (SCFAs) are the end products of microbial fermentation of non-digestible carbohydrates and have been reported to increase mucous secretion ([@bib11], [@bib57]). SCFAs are absorbed by the distal ileum and colon and are important sources of nutrition for epithelial cells ([@bib11], [@bib13]) to promote mucosal restitution, induce differentiation, and inhibit inflammation ([@bib13], [@bib3]). Organic acids in feces at day 4 and day 8 are shown in [Figure 7](#fig7){ref-type="fig"}D. Acetate concentration was decreased in the combination group, compared with the clindamycin administration group. Additionally, n-butyrate was seen only in the control group and CBM 588 administration group at day 4 but was found in all groups at day 8. The combination group showed a similar n-butyrate concentration as the clindamycin administration group. However, the combination group showed a higher ratio of n-butyrate/lactate than the clindamycin administration group at day 8 ([Figure 7](#fig7){ref-type="fig"}E). These results suggest that CBM 588 enhances the efficiency of lactate use for the production of butyrate, which is an anti-inflammatory SCFA that contributes to colon health and promotes the synthesis of mucin ([@bib7]). Taken together, our results suggest that dysbiosis caused by antibiotics affects gut metabolite production in the resident microbiome. However, CBM 588 enhances carbohydrate metabolites and the production efficiency of n-butyrate, thus protecting the colon epithelial barrier, along with mucin production. Additionally, CBM 588 enhanced "lipid metabolism," "arachidonic acid metabolism," and "α-linoleic acid metabolism" pathways ([Figure 7](#fig7){ref-type="fig"}F). These results suggest that gut microbiome function shifts toward the production of prostaglandins and specialized pro-resolving lipid mediators (SPMs), including protectin D~1~ and resolvin E, to counteract colon mucosa inflammation ([@bib58]).

CBM 588 Promotes the Production of Anti-inflammatory Lipokines (Palmitoleic Acid), Prostaglandins Metabolites (15d-PGJ~2~), and Specialized Pro-resolving Lipid Mediators (Protectin D~1~) in Mouse Colon Tissue {#sec2.6}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Colon metabolites are the end products of cellular regulatory processes and have a strong correlation to phenotype. Levels of metabolites are also a predictor of a biological system\'s response to genetic and/or environmental changes. Since we found gut metabolic profile changes in lipid metabolites by the resident microbiome, we hypothesized that host colon tissue metabolic profiles would also change along with gut microbiome alternations. The PCA score plots for the control group and each treatment group are shown in [Figure 8](#fig8){ref-type="fig"}A. Samples clustered according to the treatment status of the mice (p \< 0.05). The clindamycin administration group clustered separately (p \< 0.05) from the CBM 588 administration group and combination group at day 4 but not at day 8 ([Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}). As shown in [Figure 8](#fig8){ref-type="fig"}B, a heatmap was generated by hierarchical Pearson clustering of metabolites of colon tissue. The results showed a significant difference between the control group, clindamycin administration group, CBM 588 administration group, and combination group (p \< 0.05) for 18 significant metabolites. Palmitic acid (C~16~) and palmitoleic acid (C~16~, ω-7), the monounsaturated fatty acid of palmitic acid that is classified as a lipokine, showed a higher concentration in the CBM 588 administration groups than in the clindamycin administration group and control group. Previous studies have revealed that palmitoleic acid suppresses inflammatory cytokine production and attenuates inflammation in metabolically active tissues ([@bib8], [@bib9]). Additionally, it reverses macrophage polarization through the activation of AMP-activated protein kinase via peroxisome proliferator-activated receptor γ (PPARγ) activation ([@bib9]). Previous study revealed that many intestinal bacteria can produce palmitic acid ([@bib45]). Bacteria-derived sphingolipids, which are endogenously produced from palmitic acid by serine-palmitoyl transferase, can act as signaling molecules to modulate host immune responses in the gut ([@bib28]). Then, some kinds of gut commensal bacteria in the *Bacteroidetes* phylum produce sphingolipids through bacterial serine-palmitoyl transferase. Hence, our metabolic profile analysis suggests that CBM 588 enhances palmitoleic acid production to reduce colon inflammation ([Figure 8](#fig8){ref-type="fig"}C).Figure 8CBM 588 Promotes the Production of Several Anti-inflammatory Compounds in Mouse Colon Tissue(A) PCA analysis representation of major sources of metabolite variability in the colon at day 4. Data points represent colon samples from three independent experiments (biological replicates; n = 5) injected randomly into the GC-MS.(B) Heatmaps of selected colon metabolites, generated by hierarchical clustering, were significant between the control, clindamycin, and/or CBM 588 administration groups by Kruskal-Wallis test. An FDR p value \< 0.05 was considered statistically significant, and the Benjamini-Hochberg method was used to calculate FDR p value.(C) The peak height comparison of palmitoleic acid at day 4 and day 8 in each group.(D) The concentration of 15d-PGJ~2~ at day 4 and day 8.(E) The peak height comparison of leukotriene, PGE~2~, and PGD~2~ at day 4. These results are represented with the mean ± SEM (n = 5).(F) Featured metabolic pathway from palmitic acid to palmitoleic acid, 15d-PGJ~2~, and Protectin D~1~.(G) The peak height comparison of protectin D~1~ at day 4 and day 8.These results are represented with the mean ± SEM (n = 5--10). \*p \< 0.05. Statistical analysis of the quantitative multiple group comparisons was performed using a one-way analysis of variance followed by Tukey\'s test, \*p \< 0.05.

Additionally, stearic acid (C~18~) and oleic acid (C~18~, ω-9) production were also enhanced in the CBM 588 administration groups ([Figure 8](#fig8){ref-type="fig"}B). We observed changes in COX-2 RNA expression in colon tissue, and gut residual microbiome enhanced arachidonic acid metabolism in addition to α-linoleic acid metabolism in CBM 588 administration groups ([Figure 7](#fig7){ref-type="fig"}F). Therefore, we hypothesized that CBM 588 enhanced the production of other anti-inflammatory lipid metabolites in colon tissue, since several members of the cyclopentenone family of prostaglandins and SPMs possess anti-inflammatory properties ([@bib59], [@bib22]). Consequently, we found higher concentrations of 15-deoxy-⊿^12,14^-prostaglandin (PG) J~2~ (15d-PGJ~2~) in colon tissue for the CBM 588 administration groups ([Figure 8](#fig8){ref-type="fig"}D). PGJ~2~ is formed through dehydration within the cyclopentenone ring of the endogenous PGD~2~. PGJ~2~ is then further metabolized to yield D~12~-PGJ~2~ and 15d-PGJ~2~. 15d-PGJ~2~ is a high-affinity ligand for PPARγ. Various PPARγ ligands have been reported to possess anti-inflammatory properties *in vitro* ([@bib31]). It is possible that PPARγ trans-represses the expression of pro-inflammatory mediators at the transcriptional level by inhibiting NF-kB, STAT-1, and activator protein-1 (AP-1) signaling ([@bib53]). Previous studies have revealed that 15d-PGJ~2~ inhibits chemokine expression and attenuates IκBα phosphorylation and nucleus translocation of NF-κB through a PPARγ-independent mechanism ([@bib40]). 15d-PGJ2 is also known to have a potent suppressive effect on inflammatory responses via the Akt and NF-κB pathways, independent of PPARγ activation ([@bib33]), in addition to attenuating the development of colon injury due to dinitrobenzene sulfonic acid in the IBD rat model ([@bib12]). In our study, arachidonic acid metabolism, especially 15d-PGJ~2~, was upregulated ([Figure 8](#fig8){ref-type="fig"}D), whereas COX-2 RNA expression in colon tissue was reduced by CBM 588 ([Figure 3](#fig3){ref-type="fig"}D). Our results looked like contraindicated. However, COX-1 and COX-2 can produce PGD~2,~ which is the parent compound of 15d-PGJ~2,~ from arachidonic acid ([@bib6]), and we admitted enhanced PGD~2~ production in the combination group than in the clindamycin administration group ([Figures 8](#fig8){ref-type="fig"}E and 8F). On the other hand, PGE~2~, metabolites by COX-2 from arachidonic acid, was decreased in the clindamycin administration group. Hence, our study suggests that CBM 588 enhances 15d-PGJ~2~ production in colon tissue to suppress gut inflammation ([Figure 8](#fig8){ref-type="fig"}D).

Since we found that gut metabolites enhanced "α-linoleic acid metabolism" after CBM 588 administration ([Figure 7](#fig7){ref-type="fig"}F), we hypothesized that CBM 588 also enhances the production of other anti-inflammatory metabolites derived from α-linoleic acid in colon tissue. Accumulating evidence has shown ω3 lipid metabolites to be potent anti-inflammatory lipid mediators, such as protectin D~1~ and resolvin E, which have been identified as new SPMs important in intestinal protection ([@bib22]). The resolution of inflammation is an active process with a mechanism partly linked to decreased leukocyte-endothelial interaction and reduced granulocyte trafficking by SPM that limits the host response within the affected tissue. Failure of effective resolution may lead to tissue injury ([@bib22], [@bib23]). In this study, CBM 588 enhanced protectin D~1~ levels in colon tissue ([Figure 8](#fig8){ref-type="fig"}G) at day 4 and day 8. These results demonstrate that many types of metabolites with anti-inflammatory effects in host colon tissue, such as palmitoleic acid, 15d-PGJ~2~, and protectin D~1~, have enhanced production under CBM 588 treatment in an antibiotic-induced colitis model. This is the first study to show that probiotics enhance anti-inflammatory lipokines, PGs metabolites, and SPMs, to protect colon tissues from epithelial damage.

Discussion {#sec3}
==========

The intestinal epithelium is a critical barrier for protection against potential harmful microbiota or pathogens ([@bib50]). The epithelial barrier can be damaged with antibiotics, and CBM 588, used as a probiotic in Japan, has been shown to protect the epithelial barrier ([@bib24]). However, the mechanism of protection is not entirely clear. Here we demonstrate that CBM 588 indirectly induces the differentiation of lymphocytes to IL-17A-producing γδT cells and IL-17A-producing CD4 cells in cLP to repair the damaged epithelium. Additionally, many types of metabolites with anti-inflammatory effects in host colon tissue, such as palmitoleic acid, 15d-PGJ~2~, and protectin D~1~, have enhanced production under CBM 588 treatment in an antibiotic-induced colitis model.

Similar to previous work, our studies have revealed that antibiotics induce gut dysbiosis and colitis ([@bib38]). Clindamycin administration resulted in a dramatic reduction in gut microbiome diversity, and it seemed as if CBM 588 did not affect the gut microbiome composition at a phylum level. However, similar to a previous *in vivo* study ([@bib24]), CBM 588 administration changed the gut microbiome at the genus level and increased the abundance of *Bifidobacterium*, *Lactobacillus,* and *Lactococcus* species. We therefore hypothesized that CBM 588 would impact many host physiological processes to maintain gut homeostasis. During antibiotic-induced dysbiosis, CBM 588 has been found to modulate inflammatory cytokines in colon tissue and exhibit a colitis-preventing effect through induction of TGF-β~1~ in experimental DSS-induced acute colitis models ([@bib35], [@bib25]). Consistent with these reports, this study showed that CBM 588 administration enhanced TGF-β~1~ expression and reduced inflammatory cytokines, including IL-1β, IL-6, IFN-γ, COX-2, and TNF-α, while increasing IL-10 expression levels in colon tissue. Other studies have revealed that the TGF-β~1~ pathway regulates inflammatory cytokine production as well as promotes the production of IL-10 ([@bib25]). Therefore, our data suggest that the anti-inflammatory effect of CBM 588 against clindamycin-induced colitis is associated with a TGF-β~1~-dependent reduction of inflammatory cytokine expression and an increase in anti-inflammatory cytokines.

To further characterize the protective effects of CBM 588 on the epithelial barrier in antibiotic-induced colitis, we investigated RNA and protein expression levels of TJs and mucin-producing protein and found that CBM 588 upregulated expression levels of MUC-2 and tight junction complex proteins, whereas clindamycin downregulated these same proteins. Several investigations have found impaired TJ complexity and the downregulation of TJs in UC, which could be a mechanism responsible for intestinal barrier dysfunction ([@bib47], [@bib49]). Another study showed that, after acute intestinal injury, intestinal-protective IL-17A could regulate TJs to limit excessive permeability and maintain barrier integrity ([@bib37], [@bib5], [@bib43]). Our results showed that CBM 588 induced an elevation of IL-17A protein expression in colon tissue. Previous study identified that γδT cells were the major source of IL-17A in cLP after DSS-induced injury, with more than 30% of cells expressing the cytokine. In contrast to γδT cells, CD4 cells only had a minor contribution to IL-17A and very few ILC3 cells were positive for IL-17A ([@bib37]). Not surprisingly, we found an increase in γδT cells and IL-17A-producing γδT cells in the combination mice group, whereas no IL-17A-producing γδT cells were detected in the clindamycin administration group. Previous study suggested that TGF-β~1~ signals are necessary for IL-17A production in γδ T cell ([@bib56], [@bib16]). And, then, IL-6 need to enhance L-17A expression of γδ T cell, while we admitted the reduction of IL-6 RNA expression in colon tissue in combination group. However, *Clostridium, Bifidobacterium*, *Lactobacillus*, and *Lactococcus,* which are capable of microbial isoprenoid biosynthesis, have previously been found to induce the differentiation of lymphocytes to γδT cells and Th17 cells to protect colon epithelial cells ([@bib54], [@bib17], [@bib67], [@bib60]). IL-17A produced by γδT cells and CD4 cells also activated the Act-1 pathway in epithelial cells to maintain barrier integrity ([@bib37]). Additionally, *Lactobacillus* can upregulate the expression of TJs and prevent the destruction of epithelial barrier function ([@bib51]). Additionally, CBM 588 does not ameliorate the colitis induced by clindamycin by using anti-IL-17A antibody. Therefore, we hypothesized that IL-17A-producing γδT cells and CD4 cells may be involved in the CBM 588 protective mechanism for the colon mucosa, and TGF-β~1~, *Bifidobacterium, Lactobacillus*, and *Lactococcus,* induced by CBM 588, play a key role in the enhanced expression of IL-17-producing γδ T cells and IL-17-producing CD4 cells in cLP to protect colon epithelial cells. Our results reveal a potent intestinal epithelial barrier protective mechanism whereby CBM 588 preserves the integrity of antibiotic-damaged epithelial surfaces.

Next, we investigated gut metabolic alterations by the resident microbiome and found CBM 588 enhanced "starch and sucrose metabolism" and "fructose and mannose metabolism." Because we observed an increased abundance in bacterial species that use starch, sucrose, fructose, and mannose as energy sources, such as *Bifidobacterium*, *Lactobacillus,* and *Lactococcus*, in our CBM 588 administration groups, we believed this microbiome change could contribute to attenuation of colon epithelial damages. This result has also been seen in our previous study ([@bib24]). Mucin is an important source of carbohydrates for commensal bacteria. Additionally, SCFA in feces produced by the resident microbiome is an end product of microbial fermentation of non-digestible carbohydrates and has been reported to increase mucous secretion ([@bib11], [@bib57]). Gut mucosal microbiome in inflamed regions can shift its composition toward bacteria that metabolize starch, sucrose, fructose, and mannose, to maintain fixed amounts of energy production through the activation of carbohydrate metabolism ([@bib34]). In our study, the combination group decreased the concentration of SCFA compared with the CBM 588 administration group, whereas CB increased in gut compared with day 0. CBM 588 produced SCFA in our previous *in vivo* study using the same dosing schedule as in this study, whereas clindamycin was admitted in fecal sample at day 8 as more than 2 μg/g ([@bib24]). Hence, we speculate the reason is that antibiotics killed many SCFA-producing bacteria in the digestive tract and the situation led to the reduction of SCFA production in clindamycin administration groups. Besides, we found that CBM 588 administration resulted in a higher ratio of n-butyric acid/lactic acid among all groups at day 8. Taken together, these results indicate that dysbiosis caused by antibiotics affected gut metabolites within the microbiome. However, CBM 588 enhanced carbohydrate metabolite production and SCFA production to protect the colon epithelial barrier. CBM 588 also enhanced the production efficiency of n-butyrate to protect the colon epithelial barrier through mucin production, as we found that MUC-2 expression levels were enhanced with CBM 588 administration. These results support the hypothesis that CBM 588 contributes to increased carbohydrate metabolism, which aids in repairing the mucosal layer of the gastrointestinal tract.

We also found enhanced lipid metabolism, arachidonic acid metabolism, and α-linoleic acid metabolism pathways in the residual gut microbiome. These results imply that the gut microbiome is shifted toward the production of monounsaturated fatty acids, PGs, and SPMs, including protectin D~1~ and resolvin E, to counteract the inflammation of colon mucosa ([@bib58]). It is known that, in addition to mammalian cells, intestinal commensal bacteria also metabolize lipids and have a unique degradation pathway that yields unique metabolites. Therefore, the type of lipid produced is dependent on intestinal microbiota, which may be a critical determinant in the regulation of inflammatory responses ([@bib22]). Colon metabolites are the end products of cellular regulatory processes and correlate strongly with phenotype. Therefore, we hypothesized that CBM 588 enhances the production of anti-inflammatory metabolites in colon tissue. Consequently, palmitoleic acid (C~16~, ω-7), which is classified as a lipokine and suppresses cytokine production ([@bib8], [@bib9]) and macrophage polarization through the activation of AMP-activated protein kinase ([@bib9]), showed a higher concentration in the CBM 588 administration groups. Additionally, we found upregulation of 15d-PGJ~2~ and protectin D~1~ in colon tissue in the CBM 588 administration groups. Lipid metabolites in host colon tissue that have potent anti-inflammatory effects, such as palmitoleic acid, 15d-PGJ~2~, and protectin D~1~, showed enhanced production with CBM 588 treatment under antibiotic-induced dysbiosis. This is the first study to show that probiotics change metabolic function in the residual gut microbiome and host colon tissue, resulting in enhanced anti-inflammatory lipokine, PG metabolites, and SPM production, which protects against colon epithelial damage. These findings suggest that the use of CBM 588, or probiotic treatment enhanced with *Bifidobacterium*, *Lactobacillus,* and *Lactococcus*, could be a potential therapeutic strategy in the control of intestinal inflammatory diseases.

In conclusion, this is the first report that CBM 588 enhances gut epithelial barrier function in mice with antibiotic-induced dysbiosis by expansion of IL-17A-producing γδT cells. Additionally, gut metabolic profiles were found to produce anti-inflammatory substances, such as palmitoleic acid, 15d-PGJ~2~, and procaine D~1~, and commensal metabolic alterations occurred between the host and gut microbiome. Our results will provide insight into the development of new probiotic treatments.

Limitations of the Study {#sec3.1}
------------------------

Our study revealed some new insights for the mechanisms to show anti-inflammatory effects and epithelial protection effects with CBM 588. However, there are some limitations. First, in microbiome analysis, it was difficult to know the exact number of total bacteria. This issue made it difficult to know if the changes of relative abundances represent an increase in these bacteria or merely a shift in hierarchy. Hence, we compared relative abundances of specific bacterial species not only for clindamycin administration group and combination group data, but also for control and CBM 588 administration group data. Since the microbiome study results revealed that CBM 588 treatment did not affect gut microbiome α-diversity and β-diversity, relative abundances results will answer several differences derived from increasing bacteria or merely a shift in hierarchy. Consequently, we thought *Bifidobacterium* and *Lactococcus* were increased in the combination group, because they were increased in the CBM 588 administration group, compared with the control group. On the other hand, *Lactobacillus* was hierarchy increased in the combination group, because *Lactobacillus* did not increase in the CBM 588 administration group . Second, γδ T cells are more abundant in the intraepithelial region than in cLP, suggesting that it would be worth investigating the effect of CBM 588 on intraepithelial γδ T cells. However, previous study provides evidences that γδT cell populations in cLP are readily able to produce IL-17A protein upon activation and that these innate T lymphocytes are the early source of tissue-protective IL-17A during gut epithelial injury ([@bib37]). Hence, we evaluated lymphocytes in cLP. Third, since we did not evaluate specific mechanism with knockout mice, we cannot conclude a definitive pathway. Additional study with IL-17A knockout mice could answer the research question stringently. However, previous study revealed that CBM 588 enhanced TGF-β~1~ expression of dendritic cell ([@bib35]), and *Bifidobacterium, Lactobacillus*, and *Lactococcus* have previously been found to induce the differentiation of lymphocytes to γδT cell and Th17 cells to protect colon epithelial cells ([@bib54], [@bib17], [@bib67], [@bib60]). Therefore, we speculate that TGF-β~1~, *Bifidobacterium, Lactobacillus*, and *Lactococcus*, induced by CBM 588, play a key role in the enhanced expression of IL-17-producing γδ T cells and CD4 in cLP to protect colon epithelial cells. Also, detailed study is needed to determine the most important metabolite and its mechanism. However, as we mentioned, each metabolite has been revealed to have anti-inflammatory effect in colon and they are related to the activation of PPARγ to show the effects. Hence, we speculate that PPARγ can play an important role, but further study needs to clear which metabolites have bigger impacts to show the effect.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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